We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current HQL market cap is 342.05M. The company's latest EPS is USD 0.8704 and P/E is 15.29.
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | |||||
| Operating Income | |||||
| Net Income |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 2.44M | 3.39M | 2.29M | 3.02M | 3.5M |
| Operating Income | 0 | 0 | 0 | 0 | 0 |
| Net Income | -70.48M | 123.05M | 64.53M | -104.6M | 22.35M |
| Quarter End | |||||
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | |||||
| Total Liabilities | |||||
| Total Equity |
| Year End 30 September 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 386.98M | 484.17M | 534.19M | 414.73M | 402.6M |
| Total Liabilities | 3.33M | 596k | 10.75M | 16.82M | 666k |
| Total Equity | 383.65M | 483.57M | 523.44M | 397.9M | 401.93M |
| Market Cap | 342.05M |
| Price to Earnings Ratio | 15.29 |
| Price to Sales Ratio | 97.72 |
| Price to Cash Ratio | 0 |
| Price to Book Ratio | 0.85 |
| Dividend Yield | 12.46% |
| Shares Outstanding | 25.68M |
| Average Volume (1 week) | 71.56k |
| Average Volume (1 Month) | 76.64k |
| 52 Week Change | 0.68% |
| 52 Week High | 14.37 |
| 52 Week Low | 11.34 |
| Spread (Intraday) | 0.43 (3.16%) |
| Company Name | abrdn Life Sciences Investors |
| Address |
100 federal street boston, massachusetts 02110 |
| Website | https://www.teklacap.com/hql.html |
| Industry | unit inv tr, closed-end mgmt (6726) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
